Antiproliferative activities of ceritinib and trametinib were first validated in human BRAF V600E melanoma cell lines WM614 and the therapy (BRAF inhibition) resistant derivative, WM164R (Supplementary Figure 3A&B).28 Trametinib and ceritinib inhibited WM164 growth while only, as expected, ceritinib had an impact on WM164R. The gene discussed is BRAF; the disease is melanoma.